Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Prasenjit Dey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6678-503X; OpenAlex author ID A5058602189; NIH RePORTER profile ID 11968962. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 3)
Trials
0
Grants
3
Labs led
1
Collaborators
38
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 grant · 2020: 1 paper · 2021: 1 grant · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper, 1 grant · 2026: 2 papers

Papers 11

  1. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  2. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  3. Pancreatic Steatosis as a Risk Factor for Pancreatic Ductal Adenocarcinoma: Pathogenesis and Clinical Implications. First author DOI 10.14309/ctg.0000000000000832↗
  4. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-2504↗
  5. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
  6. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Last author DOI 10.1016/j.ccell.2022.01.003↗
  7. Isolation and adoptive transfer of innate lymphoid cells 2 to a recipient mouse model of PDAC. Last author DOI 10.1016/j.xpro.2022.101563↗
  8. Fungal ablation and transplantation of specific fungal species into PDAC tumor-bearing mice. Last author DOI 10.1016/j.xpro.2022.101644↗
  9. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
  10. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  11. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗

Grants 3

  1. Role of type 2 immune response in pancreatic cancer tumorigenesis R01CA262822↗
  2. Targeting Malic Enzyme 3 as a Synthetic Lethality Target in Pancreatic Cancer R00CA218891↗
  3. Targeting malic enzyme 3 as a synthetic lethality target in pancreatic cancer K99CA218891↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huamin Wang · 7 shared papers, 2017–2026 · strength 0.81
  2. Ronald Anthony Depinho · 7 shared papers, 2017–2026 · strength 0.81
  3. Anirban Maitra · 7 shared papers, 2017–2026 · strength 0.81
  4. Haoqiang Ying · 6 shared papers, 2017–2026 · strength 0.70
  5. Giannicola Genovese · 5 shared papers, 2017–2026 · strength 0.57
  6. Aftab Alam · 3 shared papers, 2022 · strength 0.56
  7. Andrea Viale · 4 shared papers, 2017–2026 · strength 0.49
  8. Jason B. Fleming · 4 shared papers, 2017–2026 · strength 0.49
  9. Giulio Francesco Draetta · 4 shared papers, 2017–2026 · strength 0.49
  10. Tony Gutschner · 4 shared papers, 2017–2026 · strength 0.49
  11. Zoi Papalamprakopoulou · 1 shared paper, 2025 · strength 0.37
  12. Christos K Fountzilas · 1 shared paper, 2025 · strength 0.37
  13. Lifeng Yang · 2 shared papers, 2017–2026 · strength 0.26
  14. Di Zhao · 2 shared papers, 2017–2026 · strength 0.26
  15. Ya’an Kang · 2 shared papers, 2017–2026 · strength 0.26
  16. Deepak Nagrath · 2 shared papers, 2017–2026 · strength 0.26
  17. Alessandro Carugo · 2 shared papers, 2017–2026 · strength 0.23
  18. Virginia Giuliani · 2 shared papers, 2017–2026 · strength 0.23
  19. Timothy Paul Heffernan · 2 shared papers, 2017–2026 · strength 0.23
  20. Marco Dal Molin · 2 shared papers, 2017–2026 · strength 0.23
  21. Laura DeLong Wood · 2 shared papers, 2017–2026 · strength 0.23
  22. Michael Goggins · 2 shared papers, 2017–2026 · strength 0.23
  23. Lynda Chin · 2 shared papers, 2017–2026 · strength 0.23
  24. Vishnu Muthuraj Kumarasamy · 1 shared paper, 2024 · strength 0.21
  25. Erik S. Knudsen · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.